+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of a xeno-free autologous culture system for endothelial progenitor cells derived from human umbilical cord blood



Development of a xeno-free autologous culture system for endothelial progenitor cells derived from human umbilical cord blood



Plos one 8(9): E75224



Despite promising preclinical outcomes in animal models, a number of challenges remain for human clinical use. In particular, expanding a large number of endothelial progenitor cells (EPCs) in vitro in the absence of animal-derived products is the most critical hurdle remaining to be overcome to ensure the safety and efficiency of human therapy. To develop in vitro culture conditions for EPCs derived from human cord blood (hCB-EPCs), we isolated extracts (UCE) and collagen (UC-collagen) from umbilical cord tissue to replace their animal-derived counterparts. UC-collagen and UCE efficiently supported the attachment and proliferation of hCB-EPCs in a manner comparable to that of animal-derived collagen in the conventional culture system. Our developed autologous culture system maintained the typical characteristics of hCB-EPCs, as represented by the expression of EPC-associated surface markers. In addition, the therapeutic potential of hCB-EPCs was confirmed when the transplantation of hCB-EPCs cultured in this autologous culture system promoted limb salvage in a mouse model of hindlimb ischemia and was shown to contribute to attenuating muscle degeneration and fibrosis. We suggest that the umbilical cord represents a source for autologous biomaterials for the in vitro culture of hCB-EPCs. The main characteristics and therapeutic potential of hCB-EPCs were not compromised in developed autologous culture system. The absence of animal-derived products in our newly developed in vitro culture removes concerns associated with secondary contamination. Thus, we hope that this culture system accelerates the realization of therapeutic applications of autologous hCB-EPCs for human vascular diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052557330

Download citation: RISBibTeXText

PMID: 24086472

DOI: 10.1371/journal.pone.0075224


Related references

Xeno-free culture condition for human bone marrow and umbilical cord matrix-derived mesenchymal stem/stromal cells using human umbilical cord blood serum. International Journal of Reproductive Biomedicine 14(9): 567-576, 2016

Optimization of the culturing conditions of human umbilical cord blood-derived endothelial colony-forming cells under xeno-free conditions applying a transcriptomic approach. Genes to Cells 15(7): 671-687, 2010

Development of a Xeno-Free Feeder-Layer System from Human Umbilical Cord Mesenchymal Stem Cells for Prolonged Expansion of Human Induced Pluripotent Stem Cells in Culture. Plos one 11(2): E0149023, 2016

Endothelial progenitor cells derived from human umbilical cord blood. American Journal of Obstetrics & Gynecology 189(6 Suppl.): S225, 2003

Expansion of cord blood CD34+hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid culture. Bone Marrow Transplantation 36(1): 71-79, 2005

Culture and identification of endothelial progenitor cells from human umbilical cord blood. International Journal of Ophthalmology 3(1): 49-53, 2010

Distinct phenotypes and regenerative potentials of early endothelial progenitor cells and outgrowth endothelial progenitor cells derived from umbilical cord blood. Journal of Tissue Engineering and Regenerative Medicine 5(8): 620-628, 2011

Human umbilical cord blood-derived CD34-positive endothelial progenitor cells stimulate osteoblastic differentiation of cultured human periosteal-derived osteoblasts. Tissue Engineering. Part a 20(5-6): 940-953, 2014

Isolation, culture and identification of two types of endothelial progenitor cells from human umbilical cord blood. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(2): 387-391, 2008

Effect of aspirin on function of human umbilical cord blood-derived late endothelial progenitor cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21(4): 1032-1037, 2013

Study on culture, identification and differentiation of CD133+ endothelial progenitor cells from human umbilical cord blood. Zhonghua Wai Ke Za Zhi 45(9): 619-622, 2007

Human umbilical cord blood derived endothelial progenitor cells A novel cell source for cardiovascular tissue engineering. Circulation 104(17 Suppl.): II 761-II 762, 2001

Isolation and animal serum free expansion of human umbilical cord derived mesenchymal stromal cells (MSCs) and endothelial colony forming progenitor cells (ECFCs). Journal of Visualized Experiments 2009(32):, 2009

Vasculogenic potential of endothelial progenitor cells derived from human umbilical cord blood and their roles in neovascularization of malignant glioma. Zhonghua Bing Li Xue Za Zhi 37(1): 45-50, 2008

Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair. International Journal of Cardiology 203: 498-507, 2016